-
肺癌是严重危害民众生命和健康的常见恶性肿瘤,目前国内外肺癌的发病率和病死率还在不断上升。在城市中,肺癌的病死率占男性恶性肿瘤病死率的38%,占女性恶性肿瘤病死率的16%,均居首位[1]。目前世界上均倾向于将两类生物学行为不同的肺癌分为小细胞肺癌和非小细胞肺癌(non-small cell lung cancer,NSCLC),NSCLC的治疗效果多年来一直没有显著提高,其原因一方面是由于其生物学特性十分复杂、恶性程度高且具有多药耐药性,另一方面是因为80%的NSCLC患者确诊时已属晚期而失去手术机会。全身化疗是一种有效地治疗NSCLC的方法。多数Ⅲ期NSCLC患者的随机试验结果均显示,化疗对晚期NSCLC患者的有效率达20%~40%,1年生存率为35%~45%,中位生存期为8~9个月[1-5]。
肺癌的放射性核素分子靶向治疗
Radionuclide molecular target therapy for lung cancer
-
摘要: 肺癌严重危害民众的生命和健康,目前国内外肺癌的发病率和病死率还在不断上升。在城市中,肺癌的病死率占男性恶性肿瘤患者病死率的38 %,占女性恶性肿瘤患者病死率的16%,均居首位。尤其是非小细胞肺癌的治疗效果多年来一直没有显著提高。近年来,随着医学分子生物学技术和理论的发展以及对肺癌发病机制认识的不断深入,转染钠/碘转运体基因及分子靶向药物介导的肺癌放射性核素治疗成为治疗晚期肺癌新的研究方向。Abstract: Lung cancer harms people's health or even lives severely. Currently, the morbidity and mortality of lung cancer are ascending all over the world. Accounting for 38.08%of malignant tumor caused death in male and 16% in female in cities, ranking top in both sex. Especially, the therapy of non-small cell lung cancer has not been obviously improved for many years. Recently, sodium/iodide transporter gene transfection and the therapy of molecular target drugs mediated radionuclide are being taken into account and become the new research directions in treatment of advanced lung cancer patients with the development of technology and theory for medical molecular biology and the new knowledge of lung cancer's pathogenesis.
-
Key words:
- Lung neoplasms /
- Radioisotopes /
- Brachytherapy /
- Sodium/iodide transporter
-
[1] Van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet, 2011, 378(9804): 1741-1755. doi: 10.1016/S0140-6736(11)60165-7 [2] Patel AR, Wedzicha JA, Hurst JR. Reduced lung-cancer mortality with CT screening. N Engl J Med, 2011, 365(21): 2035. doi: 10.1056/NEJMc1110293 [3] Sox HC. Better evidence about screening for lung cancer. N Engl J Med, 2011, 365(5): 455-457. doi: 10.1056/NEJMe1103776 [4] Heuvers ME, Stricker BH, Aerts JG. Generalizing lung-cancer screening results. N Engl J Med, 2012, 366(2): 192-193. doi: 10.1056/NEJMc1111935 [5] Xie Y, Minna JD. A lung cancer molecular prognostic test ready for prime time. Lancet, 2012, 379(9818): 785-787. [6] Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol, 2012, 13(1): e23-31. doi: 10.1016/S1470-2045(11)70129-2 [7] Wang W, Li Q, Takeuchi S, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res, 2012, 18(6): 1663-1671. doi: 10.1158/1078-0432.CCR-11-1171 [8] Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol, 2012, 30(4): 433-440. [9] Politi K, Lynch TJ. Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Clin Cancer Res, 2012, 18(6): 1490-1492[2012-03-15]. http://www.ncbi.nlm.nih.gov/pubmed?term=Politi%20K%2C%20Lynch%20TJ.%20Two%20sides%20of%20the%20same%20coin%3A%20EGFR%20exon%2019%20deletions%20and%20insertions%20in%20lung%20cancer. [published online ahead of print Feb 8, 2012]. [10] Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol, 2012, 13(1): 33-42. doi: 10.1016/S1470-2045(11)70318-7 [11] Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer, 2012, 118(3): 729-739. [12] Han CB, Ma JT, Li F, et al. EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. Cancer Lett, 2012, 314(1): 63-72. doi: 10.1016/j.canlet.2011.09.012 [13] Yoshioka H, Yamamoto S, Hanaoka H, et al. In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy[J/OL]. Cancer Immunol Immunother, 2012, 61[2012-03-15]. http://www.ncbi.nlm.nih.gov/pubmed?term=Yoshioka%20H%2C%20Yamamoto%20S%2C%20Hanaoka%20H%2C%20et%20al.%20In%20vivo%20therapeutic%20effect%20of%20CDH3%2FP-cadherin-targeting%20radioimmunotherapy. [published online ahead of print Jan 6, 2012]. [14] D'Arienzo M, Cicone F, Chiacchiararelli L, et al. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan. Cancer Biother Radiopharm, 2012, 27(2): 124-133[2012-03-15]. http://www.ncbi.nlm.nih.gov/pubmed?term=D'Arienzo%20M%2C%20Cicone%20F%2C%20Chiacchiararelli%20L%2C%20et%20al.%20Three-dimensional%20patient-specific%20dosimetry%20in%20radioimmunotherapy%20with%2090Y-ibritumomab-tiuxetan.%20. [published online ahead of print Jan 27, 2012]. [15] Khawli LA, Hu P, Epstein AL. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb Exp Pharmacol, 2008, 181: 291-328. [16] Yu LK, Ju DW, Chen WP, et al. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm, 2006, 21(1): 5-14. doi: 10.1089/cbr.2006.21.5 [17] Chen SL, Yu LK, Jiang CY, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. Clin Oncol, 2005, 23(7): 1538-1547. doi: 10.1200/JCO.2005.06.108 [18] Boerman OC, Koppe MJ, Postema EJ, et al. Radionuclide therapy of cancer with radiolabeled antibodies. Anticancer Agents Med Chem, 2007, 7(3): 335-343. doi: 10.2174/187152007780618126 [19] McLendon RE, Akabani G, Friedman HS, et al. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol, 2007, 34(4): 405-413. [20] Street HH, Goris ML, Fisher GA, et al. Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm, 2006, 21(3): 243-256. doi: 10.1089/cbr.2006.21.243 [21] Hdeib A, Sloan AE. Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin Biol Ther, 2011, 11(6): 799-806. doi: 10.1517/14712598.2011.579097 [22] Yan Y, Zhang HF, Zhang YD, et al. Transfection of the human sodium/iodide symporter (NIS) gene with liposomes and the expression of the NIS protein in human lung A549 cancer cells. Chin J Clin Oncol, 2008, 5(1): 30-34. doi: 10.1007/s11805-008-0030-6 [23] Guo R, Zhang YF, Liang S, et al. Sodium butyrate enhances the expression of baculovirus-mediated sodium/iodide symporter gene in A549 lung adenocarcinoma cells. Nucl Med Commun, 2010, 31(10): 916-921. [24] Niu G, Krager KJ, Graham MM, et al. Noninvasive radiological imaging of pulmonary gene transfer and expression using the human sodium iodide symporter. Eur J Nucl Med Mol Imaging, 2005, 32(5): 534-540. doi: 10.1007/s00259-004-1715-6 [25] Shi YZ, Zhang J, Liu ZL, et al. Adenovirus-mediated and tumor-specific transgene expression of the sodium-iodide symporter from the human telomerase reverse transcriptase promoter enhances killing of lung cancer cell line in vitro. Chin Med J (Engl), 2010, 123(15): 2070-2076. [26] Kang do Y, Lee HW, Choi PJ, et al. Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression. Pathol Int, 2009, 59(2): 73-79.
计量
- 文章访问数: 2134
- HTML全文浏览量: 1141
- PDF下载量: 6